Literature DB >> 18381720

Copper(II) coordination chemistry of westiellamide and its imidazole, oxazole, and thiazole analogues.

Peter Comba1, Lawrence R Gahan, Gebhard Haberhauer, Graeme R Hanson, Christopher J Noble, Björn Seibold, Anna L van den Brenk.   

Abstract

The copper(II) coordination chemistry of westiellamide (H(3)L(wa)), as well as of three synthetic analogues with an [18]azacrown-6 macrocyclic structure but with three imidazole (H(3)L(1)), oxazole (H(3)L(2)), and thiazole (H(3)L(3)) rings instead of oxazoline, is reported. As in the larger patellamide rings, the N(heterocycle)-N(peptide)-N(heterocycle) binding site is highly preorganized for copper(II) coordination. In contrast to earlier reports, the macrocyclic peptides have been found to form stable mono- and dinuclear copper(II) complexes. The coordination of copper(II) has been monitored by high-resolution electrospray mass spectrometry (ESI-MS), spectrophotometric and polarimetric titrations, and EPR and IR spectroscopies, and the structural assignments have been supported by time-dependent studies (UV/Vis/NIR, ESI-MS, and EPR) of the complexation reaction of copper(II) with H(3)L(1). Density functional theory (DFT) calculations have been used to model the structures of the copper(II) complexes on the basis of their spectroscopic data. The copper(II) ion has a distorted square-pyramidal geometry with one or two coordinated solvent molecules (CH(3)OH) in the mononuclear copper(II) cyclic peptide complexes, but the coordination sphere in [Cu(H(2)L(wa))(OHCH(3))](+) differs from those in the synthetic analogues, [Cu(H(2)L)(OHCH(3))(2)](+) (L = L(1), L(2), L(3)). Dinuclear copper(II) complexes ([Cu(II) (2)(HL)(mu-X)](+); X = OCH(3), OH; L = L(1), L(2), L(3), L(wa)) are observed in the mass spectra. While a dipole-dipole coupled EPR spectrum is observed for the dinuclear copper(II) complex of H(3)L(3), the corresponding complexes with H(3)L (L = L(1), L(2), L(wa)) are EPR-silent. This may be explained in terms of strong antiferromagnetic coupling (H(3)L(1)) and/or a low concentration of the dicopper(II) complexes (H(3)L(wa), H(3)L(2)), in agreement with the mass spectrometric observations.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18381720     DOI: 10.1002/chem.200701778

Source DB:  PubMed          Journal:  Chemistry        ISSN: 0947-6539            Impact factor:   5.236


  8 in total

1.  EPR Methods for Biological Cu(II): L-Band CW and NARS.

Authors:  Brian Bennett; Jason M Kowalski
Journal:  Methods Enzymol       Date:  2015-07-23       Impact factor: 1.600

2.  Complex formation and stability of westiellamide derivatives with copper(II).

Authors:  Peter Comba; Nina Dovalil; Gebhard Haberhauer; Graeme R Hanson; Yuki Kato; Toshiaki Taura
Journal:  J Biol Inorg Chem       Date:  2010-05-21       Impact factor: 3.358

Review 3.  Synthetic Receptors Based on Abiotic Cyclo(pseudo)peptides.

Authors:  Stefan Kubik
Journal:  Molecules       Date:  2022-04-28       Impact factor: 4.927

Review 4.  Thiazole and oxazole alkaloids: isolation and synthesis.

Authors:  Danilo Davyt; Gloria Serra
Journal:  Mar Drugs       Date:  2010-11-05       Impact factor: 5.118

5.  Interactions of disulfide-constrained cyclic tetrapeptides with Cu(2+).

Authors:  Liyun Zhang; Zhaofeng Luo; Lidong Zhang; Liangyuan Jia; Lifang Wu
Journal:  J Biol Inorg Chem       Date:  2013-01-23       Impact factor: 3.358

Review 6.  Ribosomal peptide natural products: bridging the ribosomal and nonribosomal worlds.

Authors:  John A McIntosh; Mohamed S Donia; Eric W Schmidt
Journal:  Nat Prod Rep       Date:  2009-04       Impact factor: 13.423

Review 7.  Possible Functional Roles of Patellamides in the Ascidian-Prochloron Symbiosis.

Authors:  Philipp Baur; Michael Kühl; Peter Comba; Lars Behrendt
Journal:  Mar Drugs       Date:  2022-02-02       Impact factor: 5.118

8.  Bistratamides M and N, Oxazole-Thiazole Containing Cyclic Hexapeptides Isolated from Lissoclinum bistratum Interaction of Zinc (II) with Bistratamide K.

Authors:  Carlos Urda; Rogelio Fernández; Jaime Rodríguez; Marta Pérez; Carlos Jiménez; Carmen Cuevas
Journal:  Mar Drugs       Date:  2017-07-01       Impact factor: 5.118

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.